Business Wire

ICCPP ODM+ Will Bring the Unheard-of Double Eco-friendly Concept "Cyclo" Vape Solutions To The Vaper Expo UK 2023 Birmingham

9.5.2023 14:07:00 EEST | Business Wire | Press release

Share

With the global prevalence of disposable e-cigarettes, there are growing concerns about the environmental problems caused. As one of key influencers of electronic atomization technology companies, as well as the parent company of VOOPOO, ICCPP Group takes these problems seriously and its ODM+ business has creatively developed world’s 1st new dual environmentally-friendly disposable vape solutions, named "Cyclo" series, which combines the concept of detachable and biodegradable, ahead of the industry in advance to achieve user portability and recyclability, will be grandly unveiled at the Vaper Expo UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005592/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The "Cyclo" eco-friendly vape solutions of ICCPP ODM+ (Photo: Business Wire)

Patented PLA Material: The Key to Make Stable Biodegradability Reality The "Cyclo" series are made with our exclusive and patented PLA material, a biodegradable material that is made from starch raw materials proposed from corn, a renewable plant resources, and which can be degraded into carbon dioxide and water in 3-6 months after being recycled and landfilled in the soil, making it a more environmentally friendly material.

In addition, ICCPP has gone through thousands of trials and tests and created a unique internal structure and process to further enhance the stability of unique PLA material, making it maintain its initial strength after thousands of drop and impact tests, to greatly improve the stability and safety of PLA e-cigarette sticks, without destroying the original biodegradable advantages of the material.

Leadless and Modular Design: Making Detachability A Reality

ICCPP’s commitment to environmental sustainability goes much further than just material selection.

We have implemented a wide range of environmentally-friendly design features, including no-soldering lead-free design and pre-automated modular assembly. These design features mean that "Cyclo" vape solutions can be easily disassembled for recycling or disposal, minimizing the environmental impact of manufacturing and using processes.

Multiple Options for Atomization Coils: The Addition of Environmental Concepts

ICCPP’s commitment to environmental sustainability does not end with the product itself. We have also advanced atomization coil technology into "Cyclo" series, resulting in a longer lifespan, less material waste, and a more stable and pure taste for vapers.

The atomization coil technology in the "Cyclo" vape solutions includes the mesh coil technology and the Gene Tree ceramic coil technology. On one hand, our mesh coil technology combines different resistivity application scenarios with a unique multi-layer distribution structure to precisely control the power at a single point and precisely calculate the heat field coverage at a single point to so that the heat is evenly distributed, resulting in a stable, perfect and pure taste.

On the other hand, the Gene Tree ceramic coil technology uses the exclusive powder-free environmental-friendly technology process, nano-microcrystalline ceramic material fired at 3000°, and a multi-layer A+ grade oil guide and oil lock aperture structure to provide more stable and uniform heating. This unique combination of technologies ensures that "Cyclo" e-cigarettes solutions provide customers with more puffs, purer tastes, greater flavor consistency and a superior vaping experience, as well as less environmental concerns .

The Origin of "Cyclo": The Commitment of ICCPP to the Environment and Society

In view of these, we name the electronic cigarettes solutions "Cyclo", representing our dedication to creating a closed-loop, circular product cycle that is both environmentally-friendly and sustainable. Also,the slogan of “Cyclo” is “Cycle of all things", and it reflects our dedications and determination to promoting environmental sustainability in all areas of our business.

In conclusion, the "Cyclo" series of e-cigarettes are the perfect choice for those who want an environmentally-friendly and sustainable vaping experience. With biodegradable materials, recyclable design features, cutting-edge atomization coil technology, as well as our commitment to environmental responsibility, we invite you to join us in the journey towards a more sustainable future.

Of course, apart from “Cyclo” eco-friendly products, ICCPP ODM+ brings dozens of vapes including refillable pods and disposable pods for UK e-cigarette enthusiasts and industry experts that meet local market flavor and puff preferences and also obey local regulations. Welcome to E10 booth at NEC of Birmingham and we look forward to seeing you on May 12th-14th 2023.

1) About ICCPP ODM+:

ICCPP ODM+ is an innovative ODM strategic cooperation model created by ICCPP Group in 2022, which puts forward the business proposition of “branding first, product integrating technology and marketing”.

Through all-round innovations and breakthroughs in technology+, product+, flavor+, quality+, compliance+ and marketing+, ICCPP ODM+ provides more premium vape solutions and services for customers' brands, so as to bring a healthier and happier electronic atomization life to global consumers and to achieve long-term development of both customers' brands and ICCPP ODM.

2) About ICCPP Group:

ICCPP Group, the parent company of VOOPOO, is a comprehensive electronic atomization ecological group with the whole industrial chain layout. It is rapidly developing with a new business model of matrix, internationalization and platform, integrating technology R&D, product design, intelligent manufacturing, brand operation and supply chain management.

With 9 years of full industry chain layout and global localization, ICCPP's electronic atomization products and solutions have been applied in more than 70 countries worldwide, covering 100,000 offline outlets and more than 36 million consumers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Carol Lu
carol@iccpp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release

Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release

ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye